Table 4. Anti-CS and anti-HBs antibody titers after each dose and at 12 months post Dose 3.
RTS,S/AS01E | RTS,S/AS02D | |||||
N | mean | 95%CI | N | mean | 95%CI | |
Anti-CS antibodies: | ||||||
Screening, all | 85 | 0.3 | 0.3–0.3 | 84 | 0.3 | 0.3–0.3 |
- pre HBV | 40 | 0.3 | 0.3–0.3 | 40 | 0.3 | 0.3–0.3 |
- no pre HBV | 37 | 0.3 | 0.3–0.3 | 39 | 0.3 | 0.2–0.3 |
Post Dose 2, all | 74 | 80 | 63–101 | 74 | 58 | 46–73 |
- pre HBV | 35 | 109 | 79–152 | 34 | 81 | 57–114 |
- no pre HBV | 31 | 50 | 35–71 | 36 | 44 | 33–59 |
Post Dose 3, all | 73 | 207 | 172–250 | 73 | 183 | 151–223 |
- pre HBV | 35 | 238 | 187–302 | 36 | 201 | 145–278 |
- no pre HBV | 31 | 170 | 122–238 | 33 | 164 | 128–209 |
Month 14, all | 58 | 16 | 12–21 | 54 | 18 | 13–26 |
- pre HBV | 29 | 15 | 10–23 | 29 | 18 | 10–32 |
- no pre HBV | 23 | 17 | 10–28 | 21 | 17 | 10–29 |
Anti-HBs antibodies: | ||||||
Screening, all | 85 | 45 | 25–80 | 84 | 19 | 12–29 |
- pre HBV | 40 | 284 | 127–637 | 40 | 61 | 30–124 |
- no pre HBV | 37 | 8 | 5–11 | 39 | 6 | 4–9 |
Post Dose 2, all | 74 | 9228 | 4676–18210 | 74 | 3838 | 2036–7237 |
- pre HBV | 35 | 79610 | 43152–146869 | 34 | 22946 | 10115–52053 |
- no pre HBV | 31 | 1095 | 562–2135 | 36 | 770 | 385–1540 |
Post Dose 3, all | 73 | 26330 | 16578–41821 | 73 | 20068 | 13636–29533 |
- pre HBV | 35 | 94879 | 56708–158741 | 36 | 48279 | 28412–82038 |
- no pre HBV | 31 | 7982 | 5534–11511 | 33 | 8292 | 5233–13138 |
Month 14, all | 58 | 6769 | 4338–10561 | 54 | 5236 | 3421–8012 |
- pre HBV | 29 | 17851 | 10235–31136 | 29 | 8408 | 4467–15825 |
- no pre HBV | 23 | 2539 | 1723–3746 | 21 | 3100 | 1708–5625 |
Values are geometric mean titers and 95% confidence intervals expressed in EU/mL. N values for pre HBV and no pre HBV do not match up to the total due to some missing values on the pre HBV status.